Emcure Pharmaceuticals Limited – Investor Presentation Summary
Key Operational Highlights
- Strong all-round performance with increased contribution from International business (58% of total revenue)
- International Business revenue up 34.2% YoY with strong growth across Europe, RoW and Canada
- Domestic revenue growth at 10.2%, reflecting resilient performance
- Productivity gains and operating leverage help improve EBITDA margin by 50 bps
- PAT margin up 110 bps to 11.3%
- Continued productivity enhancement reflected in increasing PCPM (Productivity per Customer per Month)
Key drivers of operational performance:
- Strong orderbook performance in ARV segment
- Scaling up of in-house developed portfolio across key international markets
- Market share gains and new launches in Canada
- Growth across CNS, women's health franchise and cardiometabolics range in domestic market
Segment-wise Performance
- International Business: Revenue ₹14,851 million, up 34.2% YoY
- RoW: Revenue ₹5,218 million, up 44.8% YoY
- EU: Revenue ₹5,367 million, up 32.8% YoY
- CA: Revenue ₹4,266 million, up 24.6% YoY
- Domestic Business: Revenue ₹10,812 million, up 10.2% YoY
Explanation of significant changes in segment performance:
- International growth driven by strong EU and steady U.K. performance with continued base business execution
- Liposomal Amphotericin B contribution continues to grow in European markets
- Canada growth balanced in both Quebec and rest of Canada markets through market share gains and new launches
- Domestic performance supported by normalized Zuventus performance and growth across chronic segments
Financial Highlights
Revenue: ₹25,663 million
EBITDA: ₹5,080 million
PAT: ₹2,925 million
EBITDA Margin: 19.7% (up 50 bps YoY)
PAT Margin: 11.3% (up 110 bps YoY)
Gross Profit: ₹15,073 million
Gross Profit Margin: 58.4%
Profit Before Tax (PBT): ₹3,935 million
Effective Tax Rate: 25.7%
Adjusted Profit After Tax: ₹2,909 million
Adjusted PAT Margin: 11.3%
YoY/QoQ comparison:
- Revenue: Up 16.1% YoY from ₹22,095 million; Up 4.0% QoQ from ₹24,681 million
- EBITDA: Up 25.8% YoY from ₹4,039 million; Up 4.6% QoQ from ₹4,855 million
- PAT: Up 36.2% YoY from ₹2,148 million; Up 20.0% QoQ from ₹2,437 million
Drivers of financial performance:
- Higher revenue growth across both domestic and international segments
- Operating leverage benefits
- Productivity gains
Geographical Revenue Split
Domestic vs Export Revenue:
- Domestic: ₹10,812 million, 42% of Total
- International: ₹14,851 million, 58% of Total
Regional Breakdown:
- Europe: ₹5,367 million
- Canada: ₹4,266 million
- Rest of World: ₹5,218 million
Strategic & R&D Initiatives
- Gennova Biopharmaceuticals now a wholly-owned subsidiary, strengthening biologics and biosimilars capabilities
- Mr. Samit Mehta to lead Gennova as CEO while continuing to anchor Group's biologics and biosimilars capabilities
- Signed royalty-free, non-exclusive voluntary licensing agreement with MSD for alimatravir, a once-monthly oral PrEP candidate in late-stage development
- 15+ products approved across Asia, Africa and LATAM in Q1 FY27
- Expanded into 3 new territories
- Received one product approval and launched two new products in Canada
Management Commentary & Growth Outlook
- Leadership strengthened with Mr. Satish Mehta to take over as Chairman (in addition to existing role as Managing Director & CEO) post conclusion of upcoming AGM
- Mr. Samit Mehta appointed COO of Emcure Pharmaceuticals with broader oversight of Group's R&D, operations and licensing activities
- Product pipeline provides continued visibility for sustained growth over the medium term
- Recent MASH indication for Poviztra® to help expand beyond traditional cardio-metabolics franchise